科笛(02487.HK)新药CU-20401临床展现出显著且稳健疗效优势

阿斯达克财经
29 Nov 2024

科笛(02487.HK) 公布,其潜在1类新药CU-20401 (重组突变胶原酶)于中国开展的用于治疗颏下脂肪堆积的II期临床试验已获得顶线数据。数据显示,该临床试验达到主要研究终点,结果具有统计学显著性及临床意义。

分析结果显示,于有效性方面,主要疗效终点数据显示,低剂量CU-20401组和高剂量CU20401组的治疗有效率均高于安慰剂对照组,且有效率差异均具有统计学意义。次要疗效终点数据也展现出类似的疗效优势。整体上,CU-20401展现出显著且稳健的疗效优势,安全性良好。(jl/w)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10